Business
Thermo Fisher Scientific Completes Acquisition of Clario Holdings, Inc.
WALTHAM, Mass., March 24, 2026--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the completion of its acquisition of Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials, for $8.875 billion in cash, plus potential additional earnout and other payments, largely dependent on performance. With the transaction complete, the Clario business will become part of Thermo Fisher’s Laboratory Products and Biopharma Services
About this update from Thermo Fisher Scientific Inc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1590,"height":341,"url":"https://media.zenfs.com/en/business-wire.com/22a6b8dd3ca51a65ed9e60e160278436"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LBVjg38u6LFj8GeNTkXaeQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwNg--/https://media.zenfs.com/en/business-wire.com/22a6b8dd3ca51a65ed9e60e160278436","width":960,"height":206},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/3cKWi2Fowq6Jbg4nRu.qWw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MTQ-/https://media.zenfs.com/en/business-wire.com/22a6b8dd3ca51a65ed9e60e160278436","width":1200,"height":257}},"lazy":false},{"type":"text","content":"Further strengthens Thermo Fisher’s position as the trusted partner to pharma and biotech customers, delivering important customer benefits","length":139,"tagName":"p","attribs":{}},{"type":"text","content":"Attractive return profile given high growth and strong margin profile of Clario, and meaningful synergies – reflecting the company’s disciplined approach to capital deployment","length":175,"tagName":"p","attribs":{}},{"type":"text","content":"WALTHAM, Mass., March 24, 2026--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the completion of its acquisition of Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials, for $8.875 billion in cash, plus potential additional earnout and other payments, largely dependent on performance. With the transaction complete, the Clario business will become part of Thermo Fisher’s Laboratory Products and Biopharma Services segment.","length":526,"tagName":"p"},{"type":"text","content":"Clario’s industry-leading solutions are highly complementary to Thermo Fisher’s clinical research offerings, enabling customers to gain critical insights from patient data to improve decision-making, accelerate innovation and drive greater productivity. Clario integrates clinical trial endpoint data from devices, sites and patients, enabling customers to collect, manage and analyze clinical evidence digitally across every phase of drug development, supporting faster, more confident trial decisions. The company’s platform has supported approximately 70% of FDA and EMA novel drug approvals over the past dec...